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Background: Some studies have demonstrated dexmedetomidine has anti-inflammatory effect on septic rats. However,
the mechanism of how dexmedetomidine exerts these effects is still remained unknown. This study was designed to
investigate the mechanism of how dexmedetomidine inhibits the production of inflammatory mediators in cecal ligation
and puncturinduced septic rats.
Methods: 48 Sprague-Dawley rats were randomly divided into six groups: sham-operated (sham) group, cecal ligation
and puncture (CLP) group, dexmedetomidine 5 μg/kg (DEX5) group, dexmedetomidine 10 μg/kg (DEX10) group,-
dexmedetomidine + yohimbine (DEX10 + Yoh) group and yohimibine group (Yoh). Blood, bronchoalveolarlavage
fluid (BALF) and lung tissues in each group were collected at six hours after dexmedetomidine or yohimbine treatment,.
Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in BALF and plasma were measured by enzyme-linked
immunosorbent assay (ELISA). Toll-like receptor-4(TLR4) and myeloid differerntiation factor(MyD88) expression
were measuredby quantitative PCR, and extracellular signal-regulated kinase (ERK) 1/2 phosphorylation were
determined by western blott.
Results: Compared with CLP group, dexmedetomidine significantly decreased not only the production of TNF-α and
IL-6 both in plasma and BALF, but also inhibited the expression of TLR4 and MyD88 in mRNA level and the activation of
ERK1/2 and NF-κB in the lung tissues of CLP-induced septic rats. All these effects could not be reversed by yohimibine.
Conclusions: Dexmedetomidine treatment can effectively reduce the generation of inflammatory mediators in the
plasma and BALF of CLP-induced septic rats. These effects of dexmedetomidine rely on TLR4/MyD88/MAPK/ NF-κB
signaling pathway and are independent of α2-adrenoceptor.
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Sepsis is one of the major cases in intensive care unit
(ICU) and has a very high mortality rate associated with
hemodynamic instability, multiple organ dysfunctions
(MODS), abnormal platelet and disseminated intravascular
coagulation (DIC) [1]. All these pathophysiological process
involves the uncontrolled over expression of inflammatory
cytokines such as TNF-α,IL-8 and IL-6 et al. [2-5].
Dexmedetomidine is a selective α2-adrenergic receptor
agonist, with sedative, antianxiety, sympatholytic and
hemodynamic stability characteristics [6]. Somestudies have
demonstrated that dexmedetomidine can reduce the dosage
of other anesthesia-related drugs used in perioperative* Correspondence: jianxingzhang2014@163.com
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unless otherwise stated.period and help to keep hemodynamic stable and almost
has no respiratory depression effect during sedation or
anesthesia [7-9]. In addition, dexmedetomidine has also
been revealed to have anti-inflammation effect on septic
rats [10]. However, the molecular mechanism of how dex-
medetomidine exerts these effects in endotoxemia or sepsis
is still remained unknown.
As the major receptors for patheogen-associated mo-
lecular patterens(PAMPs), Toll-like receptors(TLRs)
belong to transmenbrane protein family and play a crit-
ical role in the regulation of inflammatory and innate
immune responses [11]. Of them TLR4 is required for
the recognition and subsequent signal transduction of
LPS signal pathway [12,13]. After binding to TLR4, LPS
activates multiple intracellular signaling molecules, in-
cluding the mitogen-activated protein kinase (MAPK)This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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N-terminal kinase (JNK) or p38],and nuclear factor-κB
(NF-κB) [14]. The activation of NF-κB induces the
transcription of proinflammatory cytokines such as
TNF-α and IL-6 [15].
In this study, we designed to investigate the effect of
dexmedetomidine on TNF-α and IL-6production in the
plasma and BALF of CLP induced septic rats. Since
TLR4/MyD88/MAPK/NF-κB signal pathway plays a critical
role in regulating the generation of inflammatory cytokines
in endotoxemia or sepsis [16]. We also examed the effects
of dexmedetomidine on these signal molecules in septic
rats. We just hypothesized that the anti-inflammatory effect
of dexmedetomidine is relevant to TLR4/MyD88/MAPK/
NF-κB signal transduction pathway.
Methods
Animals
Male Sprague-Dawley rats (180-220 g) were obtained
from the Southern Medical University Animal Center
(Guangzhou,China). All animal procedures were ap-
proved and conducted in accordance with the guidelines
for the care and use of animals of the ethics committee
of Southern Medical University.
Cecal Ligation and Puncture (CLP) operation
Rats were anesthetized by an intraperitoneal injection of
pentobarbital sodium 50 mg/kg. Polymicrobial sepsis was
induced by CLP as previously described [17]. The whole
process was performed under sterile conditions with the
abdominal skin sterilizedby75% alcohol. Laparotomy was
conducted through 2 cm lower-midline incision. Cecum
was exposed and ligated immediately distal to the ileocecal
valve to avoid intestinal obstruction and then punctured
twice with a 22-gauge needle, squeezed gently to force out
a small amount of feces, and returned to the abdominal
cavity. The abdomen is closed with 4-0 silk sutures in
two layers.
Experimental protocal and surgical procedures
Forty-eight Sprague-Dawley (SD) ratswere randomly di-
vided into six groups: sham operation(sham group, n = 8),
CLP (CLP group, n = 8), Dexmedetomidine 5 μg/kg(DEX5
group, n = 8), Dexmedetomidine 10 μg/kg(DEX10 group, n
= 8), Dexmedetomidine 10 μg/kg + yohimbine1.0 mg/kg
(DEX10 + Yoh group, n = 8), and yohimbine1.0 mg/kg(Yoh
group, n = 8). Dexmedetomidine and yohimbine were
injected through caudal vein immediately after the CLP or
sham operation was done.
Blood sample, bronchoalveolar Lavage (BAL) fluid and
lung tissues collection
Six hours later, blood samples of the animals in each
group were collected from inferior vena cava. The leftlungs were removed and rinsed several times in ice-
saline, then dried with filter paper, and stored at -80°C
for subsequent protein detection. The right lungs were
lavaged five times with 10 ml cold sterile saline through
a tracheostomy tube. Then the BAL fluid(BALF) was
collected and centrifuged at 3200 rpm, 4°C(Eppendorf
5804R; Eppendorf, Hamburg, Germany) to collected the
supernatant for the measurement of TNF-α and IL-6by
enzyme-linked immunosorbent assays (ELISA) accord-
ing to the instruction of the kits(R&D Systems Inc,
Minneapolis, MN, USA).
Quatitative PCR(qPCR) assay of TLR4 mRNA and
MyD88mRNA in lung tissuses
The mRNA expression of TLR4 and MyD88 in lung tis-
sues was analyzed by qPCR. The total RNA was isolated
from lung tissuses of each group by Trizol regent
(Gibco-BRL), according to the manufactures’s instruc-
tions. 5 μg of total RNA was reverse-transcribed into
cDNA, and the PCR reaction mixtures were prepared by
SYBR Green qPCR master mix (Toyoho Co., Ltd.,
Osaka, Japan). β-actin was used as the internal control.
Primers (Daan Gene, Guangzhou, China) were designed
with sequences as follows: Forward: 5′- AACCCTAAGGC
CAACAGTGAAAAG-3′ and reverse: 5′-TCATGAGGTA
GTCTGTCAGGT-3′ for β-actin; and Froward: 5′-GCCG
GAAAGTTATTGTGGTGGT-3′ and reverse: 5′-ATGGG
TTTTAGGCGCAGAGTTT-3′for TLR4; and Forward: 5′-
ACCGCATCGAGGAGGACTG-3′ and reverse: 5′-CTGT
GGGACACTGCTCTCCA-3′ for MyD88. The relative
expression levels of TLR4 and MyD88 mRNA in the lung
tissues were determined by the2-ΔΔCT method.
Western blot for P-ERK and NF-κB
Snap-frozen rats lung tissues(50 μg) was homogenized
and centrifuged at 12,000 rpm at 4°C for 20 min, then
the supernatant was collected. Nuclear extracts were
collected to analyze the nuclear translocation of NF-κB
p65 protein by western blot. The samples were normalized
for equal amounts of total protein assayed by bicinchoni-
nic acid(BCA) method. Fifty micrograms protein from
each sample was separated on a sodium dodecyl sulfate-
polyacrylamide gel and transferred to PVDF membranes.
The membranes were blocked with 5% nonfat milk and
incubated overnight with primary anti-Phospho-ERK anti-
body and anti-NF-κB p65 antibody at 4°C. Next day the
membranes were incubated with the corresponding HRP-
conjugated secondary antibody at room time for 1 hour.
Cellular GAPDH protein was immunodetected as the
internal standard.
Statistical analysis
All data are presented as the mean ± standard devi-
ation. The data was proved as normal distribution by
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results were analyzed by one-way analysis of variance with
the Bonferroni test for variances. P < 0.05 was considered
to indicate a statistically significant difference. Graphs and
figures were madewith Graphpad Prism 5.01 (GraphPad
software, CA, USA).
Result
Dexmedetomidine reduced the generation of TNF-α and
IL-6 in the BALF and plasma
As shown in Figure 1, TNF-α and IL-6 in the BALF and
plasma of CLP and yohimibine groups were increased
obviously, compared with those of the sham group (P <
0.05). Yohimibine had no effect on the production of TNF-
α and IL-6 in the BALF and plasma of CLP-induced sepsis
(P > 0.05). As we expected, dexmedetomidine (5 μg/kg and
10 μg/kg) effectively inhibited the increase of TNF-α and
IL-6 in the plasma and BALF of CLP-induced septic rats
(P < 0.01). This effect of dexmedetomidine could not be
reversed by yohimibine (a kind of α2-adrenoceptor antag-
onist). All these results indicated that dexmedetomidine
can inhibit the generation of inflammatory mediators such
as TNF-α and IL-6 during sepsis and this effect is inde-
pendent of its α2-adrenoceptor activation effect.Figure 1 ELISA analysis of TNF-α and IL-6 expression in BALF and plasma
yohimbine(1.0 mg/kg) for six hours after CLP or operation. ELISA analysis
were presented as the mean ± standard deviation.*P < 0.05 and **P < 0.01Dexmedetomidine inhibited the expression of TLR4 and
MyD88 in the lung tissues of CLP-induced septic rats
Since TLR4 is required for LPS recognition and MyD88
is important for the downstream signal transduction, we
measured the expression of TLR4 and MyD88 in lung
tissues of all the six groups. Compared with sham group,
CLP-induced sepsis dramatically increased TLR4 and
MyD88 mRNA expression in both CLP and yohimibine
groups (P < 0.01). Meanwhile dexmedetomidine with a
dose of either 5 μg/kg or 10 μg/kg significantly inhibited
CLP-induced TLR4 and MyD88 mRNA expression and
this effect could not be reversed by yohimbine (P < 0.01)
(Figure 2).
Dexmedetomidine inhibited the activation of ERK1/2 and
NF-κB
The activation of ERK1/2 and NF‑κB is critical for
the production of inflammatory cytokines such as
TNF-α and IL-6, during endotoxemia or sepsis [16].
To measure the effect of dexmedetomidine on the
activation of ERK1/2 and NF‑κB, lung tissues in each
group were homogenized and the supernatant was
collected. Compared with the sham group, CLP-
induced sepsis dramatically promoted the activation. Rats were treated with dexmedetomidine (5 μg/kg or 10 μg/kg), or
of TNF-α, and IL-6 expression in BALF (A) and plasma (B). The data
vs. the sham group; #P < 0.05 and ##P < 0.01vs. CLP group,n = 8.
Figure 2 The expression of TLR4 mRNA (A) and Myd88 mRNA (B) in lung tissues. Rats were treated with dexmedetomidine (5 μg/kg or 10 μg/kg), or
yohimbine(1.0 mg/kg) for six hours after CLP or operation. The expression of TLR4 mRNA (A) and Myd88 mRNA (B) in lung tissues were
measured by RT-PCR . Datas were presented as the mean ± standard deviation. *P < 0.05 and **P < 0.01 vs. the sham group; #P < 0.05 and
##P < 0.01vs. CLP group, n = 8.
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(P < 0.01). Dexmedetomidine with a dose of either
5 μg/kg or 10 μg/kg significantly inhibited CLP-induced
ERK1/2 and NF‑κB activation and this effect could not be
reversed by yohimbine(P < 0.01) (Figure 3).Figure 3 Western blot analysis of P-ERK and NF-κB p65. Rats were treated wi
six hours after CLP or operation. P-ERK and NF-κB p65 activation in lung tissue
analysis of the western blot were shown in (B) and (C). Data were presented
group;#P < 0.05 and ##P < 0.01vs. CLP group,n = 8.Discussion
Our study presented a new evidence that yohimbine,
α2-adrenoceptor antagonists, couldn’t reverse the anti-
inflammatory effect of dexmedetomidinein septic rats.
Dexmedetomidine treatment (either 5 μg/kg or 10 μg/kg)th dexmedetomidine (5 μg/kg or 10 μg/kg), or yohimbine(1.0 mg/kg) for
s were analyzed by Western blot (A); The correspondingly gray intensity
as the mean ± standard deviation. *P < 0.05 and **P < 0.01 vs. the sham
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TNF-α in the plasma and BALF of CLP-induced septic
rats. Meanwhile, dexmedetomidine also inhibited the ex-
pression of TLR4 and MyD88 and the activation of ERK1/
2 and NF-κB in the lung tissues of CLP-induced septic
rats, indicating that the anti-inflammation effect of dex-
medetomidine in sepsis maybe base on TLR4/MyD88/
ERK1/2/NF-κB signal pathway.
Since dexmedetomidine is a selective α2-adrenergic
receptor agonist, we wondered whether the anti-
inflammation effect of dexmedetomidine depends on
its α2-adrenoceptor activation effect, however so far
there is few study focusing on this area. So we built
yohimibine group to test our hypothesis, however, yo-
himbine failed to reverse the anti-inflammation effect
of dexmedetomidine, indicating that the protective ef-
fect of dexmedetomidine on CLP-induced septic rats
is independent of α2-adrenoceptor. So far, human tri-
als and animal experiments have demonstrated that
the generation of inflammatory cytokines, including
TNF-α and IL-6, is one of the important characteristics of
sepsis, and excessive inflammatory response can lead to
acute lung injury [18]. As we know, dexmedetomidine is a
potent and highly specific α2-adrenergic agonist with
strong anti-inflammatory effects [19-22]. Qiao et al. found
that dexmedetomidinecould lessen systemic inflammation
and increase survival rate in septicor endotoxin-induced
shock of rats [23,24]. Moreover, Venn et al. found that
dexmedetomidine sedation could decrease the production
of inflammatory cytokines, such as IL-1β,TNF-α and IL-6
in severe sepsis patients [25,26]. In our study, dexmedeto-
midine treatment at a dose of either 5 μg/kg or 10 μg/kg
effectively reduced the generation of TNF-α and IL-6,and
this effect,however, could not be reversed by yohimbine.
These results showed the anti-inflammatory effect of
dexmedetomidine in sepsis is independent of its α2-
adrenoceptor activation ability.
TLR4 is a transmembrane receptor protein with extra-
cellular leucine-rich repeated domains and a cytoplasmic
signaling domain, specifically recognizing endogenous
molecules released from damaged or ischemic tissues
termed danger-associated molecular patterns (DAMPs),
and pathogen associated molecular patterns(PAMPs),
including sepsis [27,28]. TLR4 involves in immune re-
sponses, especially in the activation of innate immunity
against foreign pathogens and microorganisms, in
addition, TLR4 also triggers adaptative immunity
[29-31]. Some studies have suggested that the association
of TLR4 with myeloid differentiation factor 88(MyD88)
may induce the production of IL-6 and TNF-α, which trig-
gers inflammatory cascade reactions [32,33].
NF-κB is an important nuclear transcription factor,
consisting of p50 and p65 subunits. It plays an important
role in immune and inflammatory responses throughregulating the expression of inflammatory cytokines,
chemokines and adhesion molecules [34]. TLR/MyD88
signaling pathway activates mitogen-activated protein
kinase (MAPK) family and NF-κB pathways, ultimately
leading to the production of inflammatory mediators.
Since the generationof IL-6 and TNF-α is highly relevant
to LPS/TLR4/MyD88/MAPK/NF-κB signal pathway in
sepsis, therefore, we verified the effect of dexmedetomi-
dine on these signal molecules in CLP-induced septic
rats. Dexmedetomidine at a concentration of either5 or
10 μg/kg could inhibit the expression of TLR4 and
MyD88, and the activation of ERK1/2 and NF-κB in
CLP-induced sepsis.
Conclusions
In summary, this study demonstrated that CLP-induced
sepsis promoted the expression of TLR4 and Myd88 and
the activation of ERK1/2 and NF-κB in lung tissue, and
ultimately induced the generation of TNF-α and IL-6 in
BALF and plasma. However, these changes of CLP-induced
sepsis could be partially inhibited by dexmedetomidine
treatment and this inhibitory of dexmedetomidine could
not be reversed by yohimbine. All these results indicated
that dexmedetomidine treatment can effectively reduce the
generation of inflammatory mediators in the plasma and
BALF of CLP-induced septic rats. This effect of dexmedeto-
midine is independent of α2-adrenoceptor and probably is
related to TLR4/MyD88/MAPK/ NF-κB signaling pathway.
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